Business Context and Reporting Period
Company: CollPlant Biotechnologies Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026 (Announcement Date: September 1, 2026)
The filing announces a corporate action regarding the Company's capital structure. CollPlant Biotechnologies Ltd. is a biotechnology company headquartered in Rehovot, Israel, filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a reverse share split and does not contain financial performance data.
Material Changes
- Reverse Share Split: The Company will effect a 1-for-10 reverse share split of its ordinary shares.
- Trading Resumption: Trading on the Nasdaq Capital Market under the new structure will commence on Friday, September 4, 2026.
- Fractional Shares: No fractional shares will be issued; all fractional amounts will be rounded to the nearest whole share.
- Derivatives Adjustment: A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable for all outstanding warrants and options.
- Identification: The new CUSIP number for the ordinary shares will be M2R51X124.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the mechanics of the share split. The primary purpose is to inform investors of the impending change in share count and trading parameters.
Investor Verification Checklist
- Verify the new CUSIP number (M2R51X124) with your brokerage to ensure proper account updates.
- Confirm the exact number of shares held post-split, noting that fractional shares are rounded to the nearest whole share.
- Review the adjusted exercise prices and share counts for any outstanding options or warrants held.
- Monitor trading activity on the Nasdaq Capital Market starting September 4, 2026.